交易 Immunovant Inc - IMVT 差价合约

交易条件

• 类型该金融市场可进行差价合约交易。了解更多:差价合约: 差价合约
• 点差: 0.15
• 长仓隔夜仓息调整长仓隔夜仓息调整保证金。您的投资$1,000.00隔夜仓息来自头寸全值的费用-0.021485 %(-$0.43)使用杠杆的交易规模（大约值）$2,000.00来自杠杆的资金 - 美元（大约值）$1,000.00前往平台: -0.02149%
• 短仓隔夜仓息调整短仓隔夜仓息调整保证金。您的投资$1,000.00隔夜仓息来自头寸全值的费用-0.000738 %(-$0.01)使用杠杆的交易规模（大约值）$2,000.00来自杠杆的资金 - 美元（大约值）$1,000.00前往平台: -0.00074%
• 隔夜调整仓息时间: 21:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价保证止损 (GSL) 费用仅在 GSL 被触发时收取。更多详情请参阅我们网站的“服务费用”页面。: 1%

• 保证金。您的投资: $1,000.00
• 隔夜仓息来自头寸全值的费用: -0.021485 %
  (-$0.43)

• 保证金。您的投资: $1,000.00
• 隔夜仓息来自头寸全值的费用: -0.000738 %
  (-$0.01)

主要统计数据

• 前收盘价: 38.49
• 开仓: 38.35
• 1 年变化: 140.14%
• 日区间: 37.95 - 38.71

交易 Immunovant Inc - IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.